While our study sample exceeds that of several prior studies of CD163 in relation to breast cancer prognosis, it is nonetheless not as large as some of the more well-characterized T cell populations like CD8+ T cells [4], and our findings need to be replicated in additional cohorts. The gene discussed is CD163; the disease is breast carcinoma.